The FDA determined the SPAXUS™ Stent to be substantially equivalent to legally marketed predicate devices, allowing for commercialization in the United States
May 1, 2026
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
The FDA determined the SPAXUS™ Stent to be substantially equivalent to legally marketed predicate devices, allowing for commercialization in the United States